Shelby County, Tenn., funds by Health and Human Services, Department of
Listing $90,582,354.23 in stimulus funds from Health and Human Services, Department of for Shelby
Note: For some programs where states do not report where money will be distributed across the state, we do not have the allocation for individual counties. Those programs include: Medicaid, unemployment benefits and food stamps. Those amounts are included in the totals for where the state agency receiving that money is located.
Amount refers to both the amount of stimulus funding going toward the project and the face value of the loan.
| Recipient | Amount | Description | Federal Dept./Agency | Date |
|---|---|---|---|---|
| GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC | $31,200,000 | Purchase of Influenza vaccines - Fluarix and FluLaval | Office of Intergovernmental Affairs and Regional Directors | 4/24/2009 |
| GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC. | $3,943,056 | Purchase of Influenza vaccines - Fluarix and FluLaval | Centers for Disease Control and Prevention | 4/24/2009 |
| SHELBY, COUNTY OF | $3,551,575 |
ARRA - Community Services Block Grant The CSBG ARRA funds were used to provide services and activities addressing employment, education, housing, nutrition, health, and emergency services.
This spending item is part of a $19,697,805 allocation.
See details
|
Administration for Children and Families | 4/10/2009 |
| SHELBY, COUNTY OF | $3,244,658 | ARRA - Early Head Start This award provides for ARRA Early Head Start Expansion funds to serve a combination of 128 children and pregnant women in Shelby County. Our program includes child care partnerships for center-based options and Healthy Start Initiative partnership for t | Administration for Children and Families | 12/04/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $2,772,027 | Trans-NIH Recovery Act Research Support A high-end instrumentation grant is requested to purchase a research- dedicated 3.0 T Siemens Verio MRI scanner for human translational and clinical imaging research at St. Jude Children's Research Hospital. St. Jude is a charitably funded institution ded | National Institutes of Health | 5/20/2010 |
| UNIVERSITY OF TENNESSEE | $2,545,633 | Trans-NIH Recovery Act Research Support Cigarette smoking is a pre-eminent public health problem, recognized as early as 1965. The rapid acquisition and addiction to cigarettes during adolescence is at the root of this continuing epidemic. A cardinal feature of smoking is the high level of indi | National Institutes of Health | 9/25/2009 |
| SHELBY, COUNTY OF | $1,598,950 | ARRA - Head Start Provides Head Start 2009/10 ARRA Cost of Living Adjustment (COLA) and quality Improvement funding for the Head Start Program. The Head Start Program provides comprehensive quality services to children and families by fostering a learning environment that | Administration for Children and Families | 6/23/2009 |
| CHRIST COMMUNITY HEALTH SERVICES INC | $1,426,315 | ARRA Health Center Integrated Services Development Initiative[g1] Christ Community Health Services (CCHS) will use the funds to initiate dental services within the Hickory Hill Health Center and relocate a small, leased dental site to a larger facility close to its Broad Avenue Health Center. The leaeased site currently p... Show more | Health Resources and Services Administration | 6/25/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $1,249,252 |
Trans-NIH Recovery Act Research Support The goal of this project is to use contemporary genomic profiling approaches to identify genetic alterations contributing to the pathogenesis and treatment outcome of high risk acute leukemia. Despite best current therapy, acute lymphoblastic leukemia rem
This spending item is part of a $1,573,220 allocation.
See details
|
National Institutes of Health | 9/30/2010 |
| UNIVERSITY OF TENNESSEE | $1,245,558 |
Trans-NIH Recovery Act Research Support Individuals born small for gestational age face severe health problems as children and increased risks as adults of essential hypertension, cardiovascular disease, type 2 diabetes and pregnancy-related hypertension and diabetes. There are two types of gen
This spending item is part of a $1,289,403 allocation.
See details
|
National Institutes of Health | 7/13/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $1,214,364 |
Trans-NIH Recovery Act Research Support Our project is relevant to the RC4 areas of 'Applying Genomics and Other High Throughput Technologies' and to 'Using Science to Enable Health Care Reform.' We will comprehensively interrogate how genomic variation affects outcome, coupled with an integrat
This spending item is part of a $1,731,842 allocation.
See details
|
National Institutes of Health | 9/30/2010 |
| UNIVERSITY OF TENNESSEE | $1,033,813 |
Trans-NIH Recovery Act Research Support The Consortium for Health Education, Economic Empowerment and Research (CHEER) NCMHD Exploratory Center of Excellence has as its primary mission to: engage in community-based collaborations to accomplish research and incorporate the role of community asse
This spending item is part of a $1,320,676 allocation.
See details
|
National Institutes of Health | 9/19/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $1,016,452 |
Trans-NIH Recovery Act Research Support In an effort to develop new targets for antibacterial drug discovery, we recently discovered that Gram positive bacteria use a unique and essential pathway to synthesize their membrane phospholipids mediated by two gene products, PlsX and PlsY. This pathw
This spending item is part of a $1,083,581 allocation.
See details
|
National Institutes of Health | 8/18/2009 |
| UNIVERSITY OF TENNESSEE | $983,815 |
Trans-NIH Recovery Act Research Support Accidental or purposeful exposure of people to high levels of radiation poses a serious immediate risk and potential long-term health risk. NO FDA approved radiomitigant effective 24-48h after radiation injury is available today. Thus, there is a critical
This spending item is part of a $2,321,862 allocation.
See details
|
National Institutes of Health | 9/25/2009 |
| UNIVERSITY OF TENNESSEE | $869,393 | Trans-NIH Recovery Act Research Support Our preliminary data indicate ischemic hearts from rats have a transient decrease in protein phosphatase 2a (PP2a) activity, and an increase in phosphorylation of phospholamban, ERK and AKT. The decrease in PP2a activity occurs concomitant with demethylat | National Institutes of Health | 8/31/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $851,732 | Trans-NIH Recovery Act Research Support We have made important progress on the Tol2 project since the revised application and the supplemental data were submitted in 2008. The most significant advance is the demonstration of germ line transmission of remobilized Tol2 transposons following thein | National Institutes of Health | 5/05/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $840,000 | Trans-NIH Recovery Act Research Support This is a renewal application to study the underlying mechanisms of activation-induced cell death (AICD) in T cells, one of the primary mechanisms of clonal deletion and therefore central to our understanding of the immune system. Here, we define AICD as | National Institutes of Health | 7/23/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $840,000 | Trans-NIH Recovery Act Research Support The goal of the proposed research is to achieve in-depth understanding of the molecular mechanisms underlying the CNS pathogenesis in neurodegenerative GM1-gangliosidosis (GM1). This lysosomal storage disease (LSD) is caused by deficiency of lysosomal 2-g | National Institutes of Health | 5/29/2009 |
| UNIVERSITY OF TENNESSEE | $833,286 |
Trans-NIH Recovery Act Research Support Alzheimer's disease is characterized by the aggregation of 13-amyloid (A13) protein in the brain, widespread neurodegeration, and cognitive decline. Our work focuses on amelioration of Alzheimer's pathology by reducing or simplifying the major brain gang
This spending item is part of a $945,128 allocation.
See details
|
National Institutes of Health | 9/04/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $831,350 | Trans-NIH Recovery Act Research Support Despite decades of work, the development of a successful HIV-1 vaccine has not yet been achieved. A better understanding of the requirements for HIV-1-specific lymphocyte activation, and the functions of activated lymphocytes, is therefore desired. The lo | National Institutes of Health | 9/25/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $788,091 | Trans-NIH Recovery Act Research Support This proposal meets the requirements of two major Challenge Areas within Clinical Research, 'Prevention of otitis media' (04-DC101), and 'Develop novel methods and address key questions in mucosal immunology' (04-AI-101). Otitis media caused by Streptococ | National Institutes of Health | 9/17/2009 |
| UNIVERSITY OF TENNESSEE | $780,989 | Trans-NIH Recovery Act Research Support The homeostatic balance between proliferation and apoptosis is essential for the intestinal epithelium to function as a physiological and structural barrier. Intestinal epithelial cells have a high rate of cell turnover accompanied by an equally high rate | National Institutes of Health | 8/14/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $777,019 |
Trans-NIH Recovery Act Research Support The Southeast Regional Center of Excellence for Emerging Infections and Biodefense (SERCEB) is an NIH/NIAID-funded consortium of institutions across the southeast established in 2003. SERCEBG??s mission is to assist the nation in developing and deploying
This spending item is part of a $1,462,023 allocation.
See details
|
National Institutes of Health | 9/11/2009 |
| UNIVERSITY OF TENNESSEE | $740,000 | Trans-NIH Recovery Act Research Support Rheumatoid arthritis is a chronic inflammatory disease of diarthrodial joints. This systemic disease is characterized by chronic synovitis, sustained by an antigen-driven immune process against one or more proteins found in cartilage. Although several ant | National Institutes of Health | 8/13/2009 |
| UNIVERSITY OF TENNESSEE | $739,583 | Trans-NIH Recovery Act Research Support C. albicans is an opportunistic human fungal pathogen that causes mucosal, cutaneous, and systemic infections including oropharyngeal candidiasis (OPC), the most frequent opportunistic infection among patients suffering from AIDS. Fluconazole and other az | National Institutes of Health | 5/21/2009 |
| UNIVERSITY OF TENNESSEE | $723,662 | Trans-NIH Recovery Act Research Support Individuals born small for gestational age have increased risks of serious illness as newborns and throughout life, including hypertension, cardiovascular disease, type 2 diabetes and pregnancy-related hypertension and diabetes. Both traditional genetics | National Institutes of Health | 8/27/2009 |
| MEMPHIS HEALTH CENTER, INC. | $702,200 | ARRA Health Center Integrated Services Development Initiative[g1] capital improvement | Health Resources and Services Administration | 6/25/2009 |
| MEMPHIS HEALTH CENTER, INC. | $702,200 | ARRA Health Center Integrated Services Development Initiative[g1] Capital improvement and expansion | Health Resources and Services Administration | 8/29/2009 |
| MEMPHIS HEALTH CENTER, INC. | $702,200 | ARRA Health Center Integrated Services Development Initiative[g1] Capital Improvement Program | Health Resources and Services Administration | 6/25/2009 |
| UNIVERSITY OF TENNESSEE | $696,063 |
Trans-NIH Recovery Act Research Support This application addresses broad Challenge Area: (01) 'Behavior, Behavior Change, and Prevention' and Specific Challenge Topic: 01-AR-101 'Integrating Behavioral and Biomedical Research Approaches in Arthritis and Musculoskeletal Diseases' Patients with r
This spending item is part of a $845,643 allocation.
See details
|
National Institutes of Health | 9/28/2009 |
| UNIVERSITY OF TENNESSEE | $666,000 | Trans-NIH Recovery Act Research Support In previous work we created congenic strains carrying the DBA/2IBG (D2) region for alcohol preference on chromosome 2, on an otherwise C57BL/6IBG (B6) background. Recently, we have done the construction and testing of interval specific congenic recombinan | National Institutes of Health | 6/05/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $661,549 | Trans-NIH Recovery Act Research Support Despite substantial progress in the past two decades, cancer remains the leading cause of death by disease in US children between 1 and 15 years of age. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and cure rates are approaching | National Institutes of Health | 8/31/2009 |
| UNIVERSITY OF TENNESSEE | $622,382 | Trans-NIH Recovery Act Research Support Because Gram-positive (G+) infections are common and can be life-threatening, it is critical to have a thorough understanding of how these pathogenic bacteria and the various molecules that they release interact with the host immune system. One bacterial | National Institutes of Health | 7/17/2009 |
| METHODIST HEALTHCARE MEMPHIS HOSPITALS | $569,384 |
Trans-NIH Recovery Act Research Support Accidental falls are among the most common reported adverse events which occur during hospitallization. Beginning Oct.1, 2008 the CMS no longer reimburses hospitals for the treatment of injuries resulting from falls which occur during hospitalization. The
This spending item is part of a $1,573,741 allocation.
See details
|
National Institutes of Health | 9/21/2009 |
| CHRIST COMMUNITY HEALTH SERVICES INC | $549,065 | ARRA Health Center Integrated Services Development Initiative[g1] Christ Community Health Services will utilize the funds to add additional capacity to its Hickory Hill Health Center located at 5366 Winchester Rd, Memphis TN 38115. CCHS will use the funds to outfit additional exam rooms, recruit andnd employ additional m... Show more | Health Resources and Services Administration | 3/23/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $540,036 | Trans-NIH Recovery Act Research Support While our knowledge on early liver development increased considerably in the past decade, much remains to be learned on how the distinct regulators of liver organogenesis operate at the molecular level. This information is necessary not only to uncover ho | National Institutes of Health | 9/03/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $533,053 |
Trans-NIH Recovery Act Research Support Acute lymphoblastic leukemia (ALL) is one of the leading causes of cancer related death in the adolescent and young adult (AYA) population. Relative to younger children with ALL, the overall outcomes in AYA ALL are significantly poorer. Whether these outc
This spending item is part of a $1,000,000 allocation.
See details
|
National Institutes of Health | 9/29/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $513,763 |
Trans-NIH Recovery Act Research Support Tuberculosis is a leading AIDS-associated, opportunistic infection and globally it has been estimated that twenty percent of AIDS patients die from tuberculosis. In this study we propose to explore and develop a novel class of nitroaromatic anti-tuberculo
This spending item is part of a $880,429 allocation.
See details
|
National Institutes of Health | 6/18/2010 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $504,000 | Trans-NIH Recovery Act Research Support This is an NCRR Competitive Revision Application (NOT-OD-09-058 - 'Enabling RPGs to Leverage NCRR Center and Center-like Programs') submitted as a supplement to R01 AI39480 (Mechanism and function of the regulatory protein LAG-3). The goal of the parent R | National Institutes of Health | 9/28/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $500,000 | Trans-NIH Recovery Act Research Support With the recent addition of a cyclotron and radiochemistry facility to our Nuclear Medicine Division, St Jude Children's Research Hospital investigators now have access to a wide variety of both known and novel radiotracers for positron emission tomograph | National Institutes of Health | 6/17/2010 |
| UNIVERSITY OF TENNESSEE | $487,241 | Trans-NIH Recovery Act Research Support In 2008 more than 200,000 American women will be diagnosed with breast cancer and many will be treated with antiestrogens. Unfortunately, many breast tumors initially respond to antiestrogens will become unresponsive over time, leading to metastasis and m | National Institutes of Health | 7/16/2009 |
| UNIVERSITY OF TENNESSEE | $466,377 | Trans-NIH Recovery Act Research Support The proposal is to purchase a modern confocal laser confocal scanning microscope (Zeiss LSM 710) with wide spectral scanning capability, high resolution, and high sensitivity for a Neuroscience Imaging Center at the University of Tennessee Health Science | National Institutes of Health | 5/13/2010 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $462,049 | Trans-NIH Recovery Act Research Support The goal of the proposed research is to achieve in-depth understanding of the molecular mechanisms underlying the CNS pathogenesis in GM1-gangliosidosis, a catastrophic neurodegenerative lysosomal storage disease (LSD) caused by deficiency of 2-galactosid | National Institutes of Health | 9/30/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $462,000 | Trans-NIH Recovery Act Research Support In humans, IL4 and TH2 cells critically impact a wide array of diseases, a prime example of which is bronchial asthma where genetic association studies have repeatedly identified both the gene locus encoding IL4 and IL13 (5q25-31) and several mutations in | National Institutes of Health | 7/23/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $462,000 | Trans-NIH Recovery Act Research Support The long-term objectives of this proposal are to determine the magnitude of PGRMC1's effect on CYP3A4 activity and if this effect is substrate specific. PGRMC1 is a hemoprotein with a cytochrome b5-like domain. PGRMC1 enhances CYP activity in yeast and in | National Institutes of Health | 7/16/2009 |
| UNIVERSITY OF MEMPHIS | $434,348 |
Trans-NIH Recovery Act Research Support Compared to handwritten charts notes, various emerging technologies could facilitate self-documenting encounters. These technologies include speech recognition and menu-driven systems, using tablet PCs and handheld devices. However, in order for these eme
This spending item is part of a $850,248 allocation.
See details
|
National Institutes of Health | 9/24/2009 |
| UNIVERSITY OF TENNESSEE | $407,000 | Trans-NIH Recovery Act Research Support The goal of this research proposal is to identify virulence factors in Francisella tularensis Schu S4. In nature, F. tularensis causes the zoonotic disease tularemia. F. tularensis is a category A select agent because of its highly infectious nature and t | National Institutes of Health | 6/04/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $405,039 | Trans-NIH Recovery Act Research Support The primary mission of St. Jude Children's Research Hospital is to find cures for children with cancer and other catastrophic diseases through research and treatment. Recent progress at St. Jude has provided a better understanding of the molecular, geneti | National Institutes of Health | 4/22/2010 |
| UNIVERSITY OF TENNESSEE | $403,880 | Trans-NIH Recovery Act Research Support Age-related macular degeneration (AMD) is characterized since its earliest stages by formation of deposits between the Bruch's membrane (BM) and the retinal pigment epithelium (RPE), termed drusen. In recent years, a role for inflammation in the pathogene | National Institutes of Health | 7/17/2009 |
| UNIVERSITY OF TENNESSEE | $399,800 | Trans-NIH Recovery Act Research Support The study aims to serve as a proof of concept model of individualized medicine in Infectious diseases that will also advance our understanding of innate immunity and chlamydial pathogenesis. The individual differences in susceptibility to various infectio | National Institutes of Health | 7/17/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $395,000 |
Trans-NIH Recovery Act Research Support The TCR:CD3 complex is one of the most important receptors in the immune system. The central theme and long-term objective of this project is to ?determine how TCR:CD3 complexity mediates the multitude of downstream functional events orchestrated by T cel
This spending item is part of a $435,000 allocation.
See details
|
National Institutes of Health | 8/10/2010 |
| UNIVERSITY OF MEMPHIS | $387,750 | Trans-NIH Recovery Act Research Support The specific aims of this project are (1) To create a working partnership among interdisciplinary stakeholders (land developers, home builders, realtors, home buyers, policy makers, and public health professionals) aimed at deepening current understanding | National Institutes of Health | 7/16/2009 |
| UNIVERSITY OF TENNESSEE | $309,440 |
Trans-NIH Recovery Act Research Support Drugs targeting the HIV virus transcriptase or protease are used in highly active antiretroviral therapy (HAART) cocktails that have prolonged the lives of AIDS patients. Unfortunately, these drugs are associated with severe toxicities, unable to control
This spending item is part of a $427,955 allocation.
See details
|
National Institutes of Health | 9/01/2009 |
| UNIVERSITY OF TENNESSEE | $296,663 |
Trans-NIH Recovery Act Research Support During retinal development, the decision to exit the cell cycle must be precisely coordinated with cell fate specification and differentiation to ensure that the correct proportion of each cell type is generated. The Rb family of proteins (Rb, p107 and p1
This spending item is part of a $313,663 allocation.
See details
|
National Institutes of Health | 8/19/2009 |
| UNIVERSITY OF TENNESSEE | $287,064 | Trans-NIH Recovery Act Research Support Taste has profound effects on smoking behavior. Most importantly, smokers of flavored cigarette have higher odds for relapse. Gustatory and other visceral sensory information are processed and integrated in the insular cortex. Damaging of insular cortex i | National Institutes of Health | 5/21/2009 |
| MEMPHIS HEALTH CENTER, INC. | $286,003 | ARRA Health Center Integrated Services Development Initiative[g1] Increase Services to Health Services | Health Resources and Services Administration | 3/27/2009 |
| MEMPHIS HEALTH CENTER, INC. | $285,003 | ARRA Health Center Integrated Services Development Initiative[g1] Increase services to Health Center | Health Resources and Services Administration | 3/27/2009 |
| MEMPHIS HEALTH CENTER, INC. | $285,003 | Increase services | Health Resources and Services Administration | 3/27/2009 |
| UNIVERSITY OF TENNESSEE | $268,045 |
Trans-NIH Recovery Act Research Support Tuberculosis is a leading AIDS-associated, opportunistic infection and globally it has been estimated that twenty percent of AIDS patients die from tuberculosis. In this study we propose to explore and develop a novel class of nitroaromatic anti-tuberculo
This spending item is part of a $880,429 allocation.
See details
|
National Institutes of Health | 6/18/2010 |
| UNIVERSITY OF MEMPHIS | $262,859 | Trans-NIH Recovery Act Research Support The parent award, HL 084007 'Computational Approach to Ligand Discovery for LPA GPCR and PPAR', includes three specific aims that collectively address a single fundamental question. Namely, what structural characteristics confer selective agonist and/or a | National Institutes of Health | 7/16/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $251,049 |
Trans-NIH Recovery Act Research Support This award supports the therapeutic work for childhood Acute Lymphoblastic Leukemia (ALL), which is the most common childhood cancer and is a leading cause of cancer-related death. This project is designed to 1) validate the key TARGET (Therapeutically A
This spending item is part of a $1,708,950 allocation.
See details
|
National Institutes of Health | 9/29/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $247,535 |
Trans-NIH Recovery Act Research Support This supplemental award provides support to Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Supplements including: 1) High Risk Acute Lymphoblastic Leukemia (HR-ALL) - Our results establish that we can use comprehensive genom
This spending item is part of a $4,023,579 allocation.
See details
|
National Institutes of Health | 9/15/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $245,749 |
Trans-NIH Recovery Act Research Support This application addresses broad Challenge Area (15) Translational Science and specific Challenge Topic, 15-AI-102*: Develop diagnostics and drugs for multiple or extensively drug-resistant tuberculosis (MDR/XDR TB). Mycobacterium tuberculosis (M. tb), th
This spending item is part of a $978,779 allocation.
See details
|
National Institutes of Health | 9/22/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $242,721 | Trans-NIH Recovery Act Research Support Like phosphorylation, protein ubiquitination is a reversible process to regulate essentially all cellular events. Misregulation of ubiquitination plays an important role in the pathogenesis of a variety of diseases, ranging from cancer to neurodegenerativ | National Institutes of Health | 3/12/2012 |
| RXBIO INC | $231,011 | Trans-NIH Recovery Act Research Support The Gastrointestinal (GI) mucosa is one of the most radiosensitive tissues, and radiation-associated GI injury could be fatal. Supported by grant 1RC1AI078512-01, we have demonstrated that Rx100 is a potent radiomitigator in the GI tract with a dose-modif | National Institutes of Health | 7/27/2009 |
| UNIVERSITY OF TENNESSEE | $215,059 | Trans-NIH Recovery Act Research Support This Administrative Supplement will focus on the studies proposed in Specific Aim 3 of the parent grant: Specific Aim 3, To Demonstrate that COMBINED mechanical stretch and moderate hyperoxia increases alveolar type II epithelial cell apoptosis via activa | National Institutes of Health | 7/16/2009 |
| SHELBY, COUNTY OF | $211,720 |
Aging Congregate Nutrition Services for States ARRA provided funding for Congregate Nutrition Services. Established in 1972 under the Older Americans Act, the program provides meals to older Americans in congregate facilities such as senior centers, adult day centers, and faith-based settings.
This spending item is part of a $1,321,639 allocation.
See details
|
Administration on Aging | 3/18/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $201,965 |
Trans-NIH Recovery Act Research Support To date, one must conclude that the pace of progress in disease control and preservation of functional integrity and quality of life for pediatric brain tumors remains below that of most other major types of childhood cancers. Recent advances in cellular
This spending item is part of a $482,421 allocation.
See details
|
National Institutes of Health | 8/18/2009 |
| UNIVERSITY OF TENNESSEE | $196,683 |
Trans-NIH Recovery Act Research Support The main objective of the parent RC-1 grant G?Development of a Novel Gastrointestinal RadiomitigatorG? (AI 078514, 09/01/07 - 02/28/10) was to determine the therapeutic efficacy of octadecenyl thiophosphate (OTP), a novel radiomitigator using mouse and no
This spending item is part of a $449,896 allocation.
See details
|
National Institutes of Health | 8/14/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $183,726 |
Trans-NIH Recovery Act Research Support To date, one must conclude that the pace of progress in disease control and preservation of functional integrity and quality of life for pediatric brain tumors remains below that of most other major types of childhood cancers. Recent advances in cellular
This spending item is part of a $482,434 allocation.
See details
|
National Institutes of Health | 8/19/2009 |
| UNIVERSITY OF TENNESSEE | $181,903 | Trans-NIH Recovery Act Research Support In order to continue to enhance and expand our goal of introducing authentic problem based learning into K- 12 schools, the NCRR SEPA Building Bridges to Health Science Literacy (BBHSl) program at the University of Tennessee Health Science Center will (1) | National Institutes of Health | 9/17/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $178,735 | Trans-NIH Recovery Act Research Support This project will develop software that is usefule for computational screening in drug discovery projects and takes advantage of otherwise idle computers. The Supplement will support the accelerated development and deployment of a distributed MM/PBSA prog | National Institutes of Health | 9/30/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $175,000 | Trans-NIH Recovery Act Research Support The innate immune system comprises several classes of pattern recognition receptors, including Toll- like receptors (TLRs), NOD-like receptors (NLRs), and RIG-1-like receptors (RLRs). TLRs recognize microbes on the cell surface and in endosomes, whereas N | National Institutes of Health | 9/18/2009 |
| BAPTIST MEMORIAL COLLEGE OF HEALTH SCIENCES INC | $172,198 | ARRA ? Equipment to Enhance Training for Health Professionals Equipment to Enhance Training for Health Professionals at Baptist Memporial College of Health Sciences. Purpose: Request is for 3 human simulators, two will replace and upgrade current simulation equipment for student learning experiences s and one will exp... Show more | Health Resources and Services Administration | 9/02/2010 |
| LEMOYNE-OWEN COLLEGE | $171,863 |
Trans-NIH Recovery Act Research Support The Consortium for Health Education, Economic Empowerment and Research (CHEER) NCMHD Exploratory Center of Excellence has as its primary mission to: engage in community-based collaborations to accomplish research and incorporate the role of community asse
This spending item is part of a $1,320,676 allocation.
See details
|
National Institutes of Health | 9/19/2009 |
| UNIVERSITY OF TENNESSEE | $170,802 |
Trans-NIH Recovery Act Research Support Polycystic kidney disease (PKD) is characterized by the formation of innumerous fluid-filled cysts that can expand to several centimeters in diameter due to aberrant cell proliferation. The insistent enlargement of cysts disrupts the normal renal archite
This spending item is part of a $461,220 allocation.
See details
|
National Institutes of Health | 11/23/2009 |
| UNIVERSITY OF TENNESSEE | $158,632 | Trans-NIH Recovery Act Research Support Hypersensitivity pneumonitis (HP) or extrinsic allergic alveolitis is an interstitial lung disease that develops following repeated exposure to inhaled environmental antigens. The disease is characterized by alveolitis and granuloma formation that in som | National Institutes of Health | 7/16/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $157,756 |
Trans-NIH Recovery Act Research Support This award supports the therapeutic work for childhood Acute Lymphoblastic Leukemia (ALL), which is the most common childhood cancer and is a leading cause of cancer-related death. This project is designed to 1) validate the key TARGET (Therapeutically A
This spending item is part of a $1,708,950 allocation.
See details
|
National Institutes of Health | 9/29/2009 |
| UNIVERSITY OF TENNESSEE | $156,420 | Trans-NIH Recovery Act Research Support The project involves the assessment of motor and executive dysfunction in three mouse models of Parkinson's disease. Upon establishing baseline performance, mice will be treated with an rAAVmediated siRNA construct to silence GD3 synthase (GD3S). The tech | National Institutes of Health | 9/24/2009 |
| UNIVERSITY OF TENNESSEE | $154,653 | Trans-NIH Recovery Act Research Support The overall goal of the parent grant for this supplement is to develop safe and effective vaccines to prevent group A streptococcal infections and their sequelae. We are requesting an administrative supplement in response to RFA NOT-OD-09-056 which, if f | National Institutes of Health | 8/23/2010 |
| UNIVERSITY OF TENNESSEE | $151,293 | Trans-NIH Recovery Act Research Support Neurotrophins play crucial roles in innervation and development of taste buds. Brain-derived neurotrophic factor (BDNF), Neurotrophin-3 (NT-3) and Neurotrophin-4 (NT-4) are members of the neurotrophin family and have been shown to influence the lingual gu | National Institutes of Health | 7/17/2009 |
| VETERANS HEALTH ADMINISTRATION | $149,580 |
Trans-NIH Recovery Act Research Support This application addresses broad Challenge Area: (01) 'Behavior, Behavior Change, and Prevention' and Specific Challenge Topic: 01-AR-101 'Integrating Behavioral and Biomedical Research Approaches in Arthritis and Musculoskeletal Diseases' Patients with r
This spending item is part of a $845,643 allocation.
See details
|
National Institutes of Health | 9/28/2009 |
| UNIVERSITY OF TENNESSEE | $148,000 | Trans-NIH Recovery Act Research Support MicroRNAs are a new class of non-coding small RNAs that negatively regulate gene expression by either degrading mRNA or suppressing protein translation. A miRNA cluster, miR-15/16, has been implicated in a variety of human diseases, such as cancer, and em | National Institutes of Health | 9/04/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $144,177 |
Trans-NIH Recovery Act Research Support To date, one must conclude that the pace of progress in disease control and preservation of functional integrity and quality of life for pediatric brain tumors remains below that of most other major types of childhood cancers. Recent advances in cellular
This spending item is part of a $482,421 allocation.
See details
|
National Institutes of Health | 8/18/2009 |
| UNIVERSITY OF TENNESSEE | $137,197 | Trans-NIH Recovery Act Research Support The Administrative Supplement to Look AHEAD will increase the scientific impact of Look AHEAD and retain and/or create new staff positions. Look AHEAD is a randomized, controlled, multi-center clinical trial comparing the long-term health effects of an i | National Institutes of Health | 9/29/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $135,323 |
Trans-NIH Recovery Act Research Support To date, one must conclude that the pace of progress in disease control and preservation of functional integrity and quality of life for pediatric brain tumors remains below that of most other major types of childhood cancers. Recent advances in cellular
This spending item is part of a $482,434 allocation.
See details
|
National Institutes of Health | 8/19/2009 |
| UNIVERSITY OF TENNESSEE | $130,237 | Trans-NIH Recovery Act Research Support The global hypothesis of the parent project is that phasic bursting in vasopressin neurons can be explained largely by the understanding of one potassium current, its modulation by Ca++, and its autoregulation by the dendritically co-released neuropeptide | National Institutes of Health | 9/28/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $129,105 |
Trans-NIH Recovery Act Research Support To date, one must conclude that the pace of progress in disease control and preservation of functional integrity and quality of life for pediatric brain tumors remains below that of most other major types of childhood cancers. Recent advances in cellular
This spending item is part of a $381,202 allocation.
See details
|
National Institutes of Health | 8/20/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $114,702 | Trans-NIH Recovery Act Research Support Activation of the stress pathway and engagement of the apoptotic program represent two fundamental cellular responses to damage. Coordination of the cellular stress response is mediated by the transcriptional activity of heat shock factor-1 (HSF-1), the p | National Institutes of Health | 9/24/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $114,694 | Trans-NIH Recovery Act Research Support The cell division kinases (CDKs) have diverse functions, most of which are prominently linked to the control of cells division and/or transcription. Our laboratory identified a novel CDK subfamily, the CDK11 protein kinases previously known as the PITSLRE | National Institutes of Health | 12/04/2009 |
| UNIVERSITY OF TENNESSEE | $112,132 | ARRA - Scholarships for Disadvantaged Students Through education research and public service the University of Tennessee Health Science Center is committed to the highest standard of achievement in all programs regardless of a student's cultural background. With this commitment in mind, those studenent... Show more | Health Resources and Services Administration | 9/03/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $108,624 | Trans-NIH Recovery Act Research Support The scope of this proposal is to study the function of mammalian lysosomal neuraminidase (NEU1) in normal cell metabolism, and the consequences of its loss in human diseases. NEU1 belongs to the ubiquitous superfamily of sialidases. Mammalian neuraminidas | National Institutes of Health | 9/24/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $105,820 | Trans-NIH Recovery Act Research Support Sphingosine 1-phosphate (S1P) is a bioactive lipid mediator found in high levels in the blood. Signaling by S1P through its G protein-coupled receptor S1P1 is critical for the emigration of T cells from lymphoid organs into circulation. FTY720, a drug tha | National Institutes of Health | 9/18/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $105,520 | Trans-NIH Recovery Act Research Support Infection by pandemic strains of influenza A virus, as well as the currently circulating H5N1 avian strains, results in a high rate of lethality, primarily due to the excessive accumulation of proinflammatory cytokines/chemokines that precedes cellular in | National Institutes of Health | 7/22/2009 |
| SHELBY, COUNTY OF | $104,230 |
Aging Home-Delivered Nutrition Services for States ARRA provided funding for Home-Delivered Nutrition Services. Established in 1978 under the Older Americans Act, the program provides meals to seniors who are homebound.
This spending item is part of a $650,653 allocation.
See details
|
Administration on Aging | 3/18/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $102,208 | Trans-NIH Recovery Act Research Support Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide. The pneumococcus is able to colonize and replicate in a number of sites in the human host including the nasopharynx (colonization), lungs (pneumoniae), blood (sepsis, and the | National Institutes of Health | 7/22/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $99,997 | Trans-NIH Recovery Act Research Support To date, one must conclude that the pace of progress in disease control and preservation of functional integrity and quality of life for pediatric brain tumors remains below that of most other major types of childhood cancers. Recent advances in cellular | National Institutes of Health | 9/22/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $99,252 | Trans-NIH Recovery Act Research Support This grant involves exploration of the function of p53 proteins in apoptosis, and in particular, the transcription-independent function of cytosolic p53 and its relationship to transcriptional effects in apoptosis. A major component of this work is based | National Institutes of Health | 9/29/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $97,684 | Trans-NIH Recovery Act Research Support Type 1 diabetes Is an autoimmune disease that occurs when autoreactive T cells attack and kill the insulin producing cells of the pancreas. Currently, the disease is treated by repeated insulin Injections, however there is no cure. Prolonged periods of un | National Institutes of Health | 8/14/2009 |
| UNIVERSITY OF TENNESSEE | $84,000 | ARRA ? Equipment to Enhance Training for Health Professionals Project TENET (Telehealth Enhancing Nurse Education and Training) is a means of improving teaching and clinical delivery as well as overall communication between healthcare practitioners and the consumer. The purpose of the proposal is to o use Telehealth t... Show more | Health Resources and Services Administration | 9/05/2010 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $83,620 |
Trans-NIH Recovery Act Research Support DESCRIPTION (provided by applicant): The primary goal of this research is to understand communication, comprehension and decision-making in Phase I childhood cancer trials. The project will take place at 6 of the most active Phase I pediatric programs in
This spending item is part of a $160,519 allocation.
See details
|
National Institutes of Health | 8/31/2009 |
| UNIVERSITY OF TENNESSEE | $81,959 | Trans-NIH Recovery Act Research Support Tuberculosis is a leading AIDS-associated, opportunistic infection and globally it has been estimated that twenty percent of AIDS patients die from tuberculosis. In this study we propose to explore and develop a novel class of nitroaromatic anti-tuberculo | National Institutes of Health | 6/04/2009 |
| UNIVERSITY OF TENNESSEE | $81,400 | Trans-NIH Recovery Act Research Support Math1, a transcription factor, is one of the critical genes for the formation of hair cells (HC) in the inner ear as shown by its loss in Math1 knockout mice. However, we recently demonstrated that genotypically Math1-null hair cells are able to be gener | National Institutes of Health | 8/14/2009 |
| SHELBY, COUNTY OF | $81,000 |
Trans-NIH Recovery Act Research Support The Consortium for Health Education, Economic Empowerment and Research (CHEER) NCMHD Exploratory Center of Excellence has as its primary mission to: engage in community-based collaborations to accomplish research and incorporate the role of community asse
This spending item is part of a $1,320,676 allocation.
See details
|
National Institutes of Health | 9/19/2009 |
| SHELBY, COUNTY OF | $80,000 |
ARRA - Prevention and Wellness--State Territories and Pacific Islands Component III will seek to enhance proactive Quitline counseling and expand media services in order to increase the number of tobacco quitters in Tennessee. Proactive counseling will be enhanced and expanded to provide Quitline c coaching support in initia... Show more
This spending item is part of a $1,002,155 allocation.
See details
|
Centers for Disease Control and Prevention | 2/06/2010 |
| GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC. | $79,522 | Purchase of Influenza vaccines - Fluarix | Centers for Disease Control and Prevention | 5/14/2010 |
| UNIVERSITY OF TENNESSEE | $71,755 | Trans-NIH Recovery Act Research Support The purpose of the this administrative supplement Notice NOT-OD-09-056 G?to provide researchers supplementary funds that can be used to accelerate the tempo of scientific research on active grants, with the ultimate goal of promoting job creation and econ | National Institutes of Health | 8/14/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $70,800 | Trans-NIH Recovery Act Research Support The long-term goal of this project is to understand the mechanisms that regulate bacterial membrane lipidbiosynthesis and explore the structure, function and diversity of the enzymes involved in this pathway. The studyof Escherichia coli has historically | National Institutes of Health | 8/03/2009 |
| CHILDREN'S BUREAU | $70,236 | ARRA - Head Start Head Start 2009 COLA and Quality Improvement Funding.The award was used to increase staff salaries and benefits, offer professional development opportunities for teachers and home visitors through tuition reimbursement for school, CDA renewals and/or trai | Administration for Children and Families | 7/07/2009 |
| UNIVERSITY OF TENNESSEE | $63,000 |
Trans-NIH Recovery Act Research Support Our plan is to develop a new therapy for heart disease. Abstract: Cardiovascular disease is a major cause of mortality and morbidity and development of therapies that address its underlying causes is an important public health priority. With better ma
This spending item is part of a $1,176,035 allocation.
See details
|
National Institutes of Health | 7/16/2009 |
| UNIVERSITY OF TENNESSEE | $59,460 | Trans-NIH Recovery Act Research Support The long-term goal of our research project is to define genetic networks controlling susceptibility and resistance of retinal ganglion cells to optic nerve damage and to characterize the early molecular signatures associated with these changes. Our worki | National Institutes of Health | 3/22/2010 |
| UNIVERSITY OF TENNESSEE | $59,237 |
Trans-NIH Recovery Act Research Support This application addresses the broad Challenge Area (05) Comparative Effectiveness Research and specific Challenge Topic, 05-GM-101: Anesthesiology Clinical Pharmacology Sepsis Trauma, Burn, and Peri-operative Injury Wound Healing. Traumatic brain injury
This spending item is part of a $980,750 allocation.
See details
|
National Institutes of Health | 9/30/2009 |
| UNIVERSITY OF MEMPHIS | $54,017 |
Trans-NIH Recovery Act Research Support The primary objective of this project is to examine factors that are associated with the effectiveness of intervention programs designed to reduce high-risk drinking among heavy drinking college students. Previous research has found similar effect sizes f
This spending item is part of a $353,473 allocation.
See details
|
National Institutes of Health | 9/09/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $53,520 | Trans-NIH Recovery Act Research Support A 5-year plan is proposed in which the candidate will establish herself as an independent investigator in Stem Cell biology and further our understanding of hematopoietic stem cells generated by embryonic stem cells (ESC-HSC). In graduate school, the cand | National Institutes of Health | 12/06/2010 |
| UNIVERSITY OF TENNESSEE | $49,903 | Trans-NIH Recovery Act Research Support This supplement to grant number 01 DK 074565-01, A Cell Biological Approach to Lipid Absorption, is designed to speed the discovery of new information related to the control of dietary lipid absorption. As is well known, obesity is a current crisis of he | National Institutes of Health | 8/24/2009 |
| UNIVERSITY OF MEMPHIS | $48,791 |
ARRA - Health Information Technology Extension Program Regional Extension Center (REC) Grant Award in the amount of $ 7,256,155 to QSource (tnREC) on February 12, 2010: to provide assistance to 1,343 priority primary health care providers (PPCPs) throughout the state of Tennessee as they transition t to the use... Show more
This spending item is part of a $9,171,540 allocation.
See details
|
Health and Human Services, Department of | 2/08/2010 |
| UNIVERSITY OF MEMPHIS | $46,985 |
Trans-NIH Recovery Act Research Support In previous work, we have developed, deployed and evaluated a novel intelligent medical training system for pathologic diagnosis and reporting. SlideTutor is an individualized, adaptive, simulation environment that provides explanations and assistance spe
This spending item is part of a $1,901,894 allocation.
See details
|
National Institutes of Health | 5/27/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $45,999 |
Trans-NIH Recovery Act Research Support This supplemental award supports the Accelerating Clinical Trials of Novel Oncologic Path Ways (ACTNOW) program for Protocol ANBL0931, which is a Phase III Study of Chimeric Antibody 14.18 in High-Risk Neuroblastoma. The primary objective of study ANBL09
This spending item is part of a $1,981,588 allocation.
See details
|
National Institutes of Health | 8/07/2009 |
| UNIVERSITY OF MEMPHIS | $42,303 | Trans-NIH Recovery Act Research Support The parent award, HL 084007 Computational Approach to Ligand Discovery for LPA GPCR and PPAR, includes three specific aims that collectively address a single fundamental question. Namely, what structural characteristics confer selective agonist and/or ant | National Institutes of Health | 6/01/2009 |
| UNIVERSITY OF TENNESSEE | $40,416 |
Trans-NIH Recovery Act Research Support Accidental falls are among the most common reported adverse events which occur during hospitallization. Beginning Oct.1, 2008 the CMS no longer reimburses hospitals for the treatment of injuries resulting from falls which occur during hospitalization. The
This spending item is part of a $1,573,741 allocation.
See details
|
National Institutes of Health | 9/21/2009 |
| UNIVERSITY OF TENNESSEE | $39,628 | Trans-NIH Recovery Act Research Support The purpose of this Administrative Supplement is to increase the tempo of the research funded under the parent grant by replacing worn and dated equipment and providing supplies for the studies outlined. As shown by our previous work funded by the parent | National Institutes of Health | 1/18/2010 |
| RHODES COLLEGE (TENNESSEE), INC. | $39,334 |
Trans-NIH Recovery Act Research Support The purpose of the requested supplement is to provide summer research experiences for a junior faculty member and 3 undergraduate students from Rhodes College. The participants from Rhodes College will assist research staff and graduate students with thr
This spending item is part of a $56,334 allocation.
See details
|
National Institutes of Health | 7/15/2009 |
| UNIVERSITY OF TENNESSEE | $36,600 | Trans-NIH Recovery Act Research Support The overall goal of the parent application is to investigate the ability of olfactory input to increase the strength of olfactory nerve (ON) synapses in an activity-dependent fashion. Specifically, we intended to answer the question of whether a brief the | National Institutes of Health | 8/14/2009 |
| UNIVERSITY OF TENNESSEE | $35,527 | Trans-NIH Recovery Act Research Support This administrative supplement grant requests Recovery Act Funds to provide up to three individuals (two students and one science educator) with part-time summer jobs over a two year period, as team members of a cutting-edge NINR-funded research study at | National Institutes of Health | 7/14/2009 |
| UNIVERSITY OF TENNESSEE | $34,273 | Trans-NIH Recovery Act Research Support The neurohypophysial hormones vasopressin (VP) and oxytocin (OT) are synthesized in the magnocellular neurons (MNCs) located within the paraventricular (PVN) and the supraoptic (SON) nuclei of the hypothalamus, and released from the neurohypophysis into t | National Institutes of Health | 7/16/2009 |
| MARRIOTT INTERNATIONAL, INC. | $34,000 |
Trans-NIH Recovery Act Research Support The Consortium for Health Education, Economic Empowerment and Research (CHEER) NCMHD Exploratory Center of Excellence has as its primary mission to: engage in community-based collaborations to accomplish research and incorporate the role of community asse
This spending item is part of a $1,320,676 allocation.
See details
|
National Institutes of Health | 9/19/2009 |
| UNIVERSITY OF TENNESSEE | $31,241 |
ARRA - Systolic Blood Pressure Intervention Trial (SPRINT) - Senior
This spending item is part of a $2,708,560 allocation.
See details
|
National Institutes of Health | 9/24/2010 |
| UNIVERSITY OF TENNESSEE | $27,790 | Trans-NIH Recovery Act Research Support Previous studies from our laboratory and those from other investigators have shown that prostanoids generated in cerebral blood vessels contribute to cerebral vasodilation produced by hypotension. Recently, we reported that arachidonic acid (AA)-induced | National Institutes of Health | 7/15/2009 |
| UNIVERSITY OF MEMPHIS | $26,741 |
Trans-NIH Recovery Act Research Support The primary objective of this project is to examine factors that are associated with the effectiveness of intervention programs designed to reduce high-risk drinking among heavy drinking college students. Previous research has found similar effect sizes f
This spending item is part of a $187,490 allocation.
See details
|
National Institutes of Health | 9/09/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $25,371 |
Trans-NIH Recovery Act Research Support This supplement award supports the Accelerating Clinical Trials of Novel Oncologic Path Ways (ACTNOW) program for Protocol ADVL0813, which is a Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination with C
This spending item is part of a $750,000 allocation.
See details
|
National Institutes of Health | 8/13/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $22,465 |
Trans-NIH Recovery Act Research Support This supplement award supports Accelerating Clinical Trials of Novel Oncologic Path Ways (ACT NOW) program for Protocol ADVL0911, which is a Phase I Dose Escalation Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Relapsed/
This spending item is part of a $1,405,307 allocation.
See details
|
National Institutes of Health | 8/12/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $21,149 |
Trans-NIH Recovery Act Research Support The funds will be used to develop, open and analyze three H1N1 studies in HIV-infected populations. The first study will determine the safety and immunogenicity of an H1N1 vaccine in HIV-infected pregnant women. The second study will determine safety an
This spending item is part of a $1,701,287 allocation.
See details
|
National Institutes of Health | 11/25/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $17,000 |
Trans-NIH Recovery Act Research Support During retinal development, the decision to exit the cell cycle must be precisely coordinated with cell fate specification and differentiation to ensure that the correct proportion of each cell type is generated. The Rb family of proteins (Rb, p107 and p1
This spending item is part of a $313,663 allocation.
See details
|
National Institutes of Health | 8/19/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $17,000 |
Trans-NIH Recovery Act Research Support The purpose of the requested supplement is to provide summer research experiences for a junior faculty member and 3 undergraduate students from Rhodes College. The participants from Rhodes College will assist research staff and graduate students with thr
This spending item is part of a $56,334 allocation.
See details
|
National Institutes of Health | 7/15/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $15,690 |
Trans-NIH Recovery Act Research Support The funds will be used to develop, open and analyze three H1N1 studies in HIV-infected populations. The first study will determine the safety and immunogenicity of an H1N1 vaccine in HIV-infected pregnant women. The second study will determine safety an
This spending item is part of a $1,701,287 allocation.
See details
|
National Institutes of Health | 11/25/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $15,000 |
Trans-NIH Recovery Act Research Support This project will take advantage of the existing infrastructure of the PHACS Study which began protocol development in 2005 after successfully competing for funding by the NICHD. This is a multicenter, multidisciplinary and collaborative study. The PHACS
This spending item is part of a $1,012,474 allocation.
See details
|
National Institutes of Health | 9/29/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $13,470 |
Trans-NIH Recovery Act Research Support The funds will be used to develop, open and analyze three H1N1 studies in HIV-infected populations. The first study will determine the safety and immunogenicity of an H1N1 vaccine in HIV-infected pregnant women. The second study will determine safety an
This spending item is part of a $1,701,287 allocation.
See details
|
National Institutes of Health | 11/25/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $8,784 |
Trans-NIH Recovery Act Research Support The funds will be used to develop, open and analyze three H1N1 studies in HIV-infected populations. The first study will determine the safety and immunogenicity of an H1N1 vaccine in HIV-infected pregnant women. The second study will determine safety an
This spending item is part of a $1,701,287 allocation.
See details
|
National Institutes of Health | 11/25/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $8,384 | Trans-NIH Recovery Act Research Support The purpose of the requested supplement is to provide summer research experiences for a junior faculty member and 3 undergraduate students from Rhodes College. The participants from Rhodes College will assist research staff and graduate students with thr | National Institutes of Health | 7/15/2009 |
| UNIVERSITY OF TENNESSEE | $7,000 |
Trans-NIH Recovery Act Research Support Chronic kidney disease (CKD) in children is a devastating illness. The prevalence of patients aged 0 ? 19 years with ESRD has grown 32% since 1990 and the mortality rate for children with ESRD receiving dialysis therapy is between 30 and 150 times that o
This spending item is part of a $525,000 allocation.
See details
|
National Institutes of Health | 9/27/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $3,999 |
Trans-NIH Recovery Act Research Support This is a translational research proposal to elucidate the mechanisms underlying apparent differences in end-organ iron deposition between patients with sickle cell anemia (SCD), thalassemia (TM) and Diamond Blackfan Anemia (DBA). Increasing numbers of
This spending item is part of a $645,010 allocation.
See details
|
National Institutes of Health | 9/10/2009 |
| ST. JUDE CHILDREN'S RESEARCH HOSPITAL | $3,999 |
Trans-NIH Recovery Act Research Support This is a translational research proposal to elucidate the mechanisms underlying apparent differences in end-organ iron deposition between patients with sickle cell anemia (SCD), thalassemia (TM) and Diamond Blackfan Anemia (DBA). Increasing numbers of
This spending item is part of a $645,010 allocation.
See details
|
National Institutes of Health | 9/10/2009 |